• IX Biopharma announced a corporate reorganization to restructure and transfer its consumer business into a new company, Ligo Pharma.
• Consumer assets to move into Ligo include a US-focused telehealth platform targeting longevity and lifestyle, supported by a 503A/503B compounding pharmacy model.
• ~40 repurposed sublingual formulations, including hormones and peptides described as ready for sale, are slated to sit in the consumer unit.
• Pharmaceuticals division remains centered on Wafermine, a sublingual ketamine wafer for acute, moderate-to-severe pain, advancing toward Phase 3.
• Reorganization follows consumer business restructuring listed as a May 2026 milestone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IX Biopharma Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: DWCXNDCTB12JI0M8) on July 03, 2026, and is solely responsible for the information contained therein.